Tangram Therapeutics
Tangram Therapeutics is a biotechnology company combining artificial intelligence and RNA interference to discover and develop novel medicines.
Its proprietary chemistry platform silences disease-driving genes in hepatocytes, and its AI platform drives target identification and siRNA design.
The pipeline includes TGM-312, a first-in-class RNAi medicine for metabolic dysfunction-associated steatohepatitis currently in Phase I/II clinical trials, and TGM-148 for bleeding disorders approaching clinical entry.
Latest News
Tangram Therapeutics Appoints Dr Laura Roca-Alonso as CEO and Board Director
Tangram Therapeutics has appointed Dr Laura Roca-Alonso as Chief Executive Officer and Executive Director of the Board, confirming her in the role after serving as Interim CEO since March 2026. Roca-Alonso, Chief Operating and Business Officer since 2020, will lead the company as it works towards clinical data on its co-lead RNAi programmes, TGM-312 for MASH and TGM-148 for bleeding disorders, over the next 12 months.
Tangram Therapeutics advances TGM-312 to MASH patient cohorts, appoints CDO
Tangram Therapeutics has progressed its MASH candidate TGM-312 into Part B (multiple ascending dose, patient cohorts) of its Phase 1/2 RESTORE-MASH trial, following favourable independent Data Monitoring Committee review and four healthy-volunteer cohorts with no serious or severe adverse events; interim patient data are expected during 2027. The company also appointed Dr Sonya Montgomery, previously Chief Development Officer at OSE Immunotherapeutics and Chief Medical Officer at Evox Therapeutics, as Chief Development Officer to lead its clinical pipeline.